These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Metagenomic next-generation sequencing of nasopharyngeal microbiota in COVID-19 patients with different disease severities. Aljabr W; Dandachi I; Abbas B; Karkashan A; Al-Amari A; AlShahrani D Microbiol Spectr; 2024 May; 12(5):e0416623. PubMed ID: 38557102 [TBL] [Abstract][Full Text] [Related]
4. The salivary and nasopharyngeal microbiomes are associated with SARS-CoV-2 infection and disease severity. Kim JG; Zhang A; Rauseo AM; Goss CW; Mudd PA; O'Halloran JA; Wang L J Med Virol; 2023 Feb; 95(2):e28445. PubMed ID: 36583481 [TBL] [Abstract][Full Text] [Related]
5. Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Nardelli C; Gentile I; Setaro M; Di Domenico C; Pinchera B; Buonomo AR; Zappulo E; Scotto R; Scaglione GL; Castaldo G; Capoluongo E Front Cell Infect Microbiol; 2021; 11():625581. PubMed ID: 33659220 [TBL] [Abstract][Full Text] [Related]
6. Nasopharyngeal microbiota profiling of pregnant women with SARS-CoV-2 infection. Crovetto F; Selma-Royo M; Crispi F; Carbonetto B; Pascal R; Larroya M; Casas I; Tortajada M; Escudero N; Muñoz-Almagro C; Gomez-Roig MD; González-Torres P; Collado MC; Gratacos E Sci Rep; 2022 Aug; 12(1):13404. PubMed ID: 35927569 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome. Rosas-Salazar C; Kimura KS; Shilts MH; Strickland BA; Freeman MH; Wessinger BC; Gupta V; Brown HM; Rajagopala SV; Turner JH; Das SR J Allergy Clin Immunol; 2021 Apr; 147(4):1226-1233.e2. PubMed ID: 33577896 [TBL] [Abstract][Full Text] [Related]
8. Alterations in the nasopharyngeal microbiome associated with SARS-CoV-2 infection status and disease severity. Gauthier NPG; Locher K; MacDonald C; Chorlton SD; Charles M; Manges AR PLoS One; 2022; 17(10):e0275815. PubMed ID: 36240246 [TBL] [Abstract][Full Text] [Related]
9. NGS analysis of nasopharyngeal microbiota in SARS-CoV-2 positive patients during the first year of the pandemic in the Campania Region of Italy. Giugliano R; Sellitto A; Ferravante C; Rocco T; D'Agostino Y; Alexandrova E; Lamberti J; Palumbo D; Galdiero M; Vaccaro E; Pagliano P; Weisz A; Giurato G; Franci G; Rizzo F Microb Pathog; 2022 Apr; 165():105506. PubMed ID: 35358660 [TBL] [Abstract][Full Text] [Related]
10. Nasopharyngeal microbiome reveals the prevalence of opportunistic pathogens in SARS-CoV-2 infected individuals and their association with host types. Gupta A; Karyakarte R; Joshi S; Das R; Jani K; Shouche Y; Sharma A Microbes Infect; 2022 Feb; 24(1):104880. PubMed ID: 34425246 [TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Infection is Associated with Age- and Gender-Specific Changes in the Nasopharyngeal Microbiome. Bozza S; Nunzi E; Frias-Mazuecos A; Pieraccini G; Pariano M; Renga G; Mencacci A; Talesa VN; Antognelli C; Puccetti P; Romani L; Costantini C Front Biosci (Landmark Ed); 2024 Feb; 29(2):59. PubMed ID: 38420819 [TBL] [Abstract][Full Text] [Related]
13. Super Dominant Pathobiontic Bacteria in the Nasopharyngeal Microbiota Cause Secondary Bacterial Infection in COVID-19 Patients. Qin T; Wang Y; Deng J; Xu B; Zhu X; Wang J; Zhou H; Zhao N; Jin F; Ren H; Wang H; Li Q; Xu X; Guo Y; Li R; Xiong Y; Wang X; Guo J; Zheng H; Hou X; Wan K; Zhang J; Lu J; Kan B; Xu J Microbiol Spectr; 2022 Jun; 10(3):e0195621. PubMed ID: 35579467 [TBL] [Abstract][Full Text] [Related]
14. Age-Related Changes in the Nasopharyngeal Microbiome Are Associated With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and Symptoms Among Children, Adolescents, and Young Adults. Hurst JH; McCumber AW; Aquino JN; Rodriguez J; Heston SM; Lugo DJ; Rotta AT; Turner NA; Pfeiffer TS; Gurley TC; Moody MA; Denny TN; Rawls JF; Clark JS; Woods CW; Kelly MS Clin Infect Dis; 2022 Aug; 75(1):e928-e937. PubMed ID: 35247047 [TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 does not have a strong effect on the nasopharyngeal microbial composition. Braun T; Halevi S; Hadar R; Efroni G; Glick Saar E; Keller N; Amir A; Amit S; Haberman Y Sci Rep; 2021 Apr; 11(1):8922. PubMed ID: 33903709 [TBL] [Abstract][Full Text] [Related]
16. Diversity, composition, and networking of saliva microbiota distinguish the severity of COVID-19 episodes as revealed by an analysis of 16S rRNA variable V1-V3 region sequences. Larios Serrato V; Meza B; Gonzalez-Torres C; Gaytan-Cervantes J; González Ibarra J; Santacruz Tinoco CE; Anguiano Hernández YM; Martínez Miguel B; Cázarez Cortazar A; Sarquiz Martínez B; Alvarado Yaah JE; Mendoza Pérez AR; Palma Herrera JJ; García Soto LM; Chávez Rojas AI; Bravo Mateos G; Samano Marquez G; Grajales Muñiz C; Torres J mSystems; 2023 Aug; 8(4):e0106222. PubMed ID: 37310423 [TBL] [Abstract][Full Text] [Related]
17. Impact of COVID-19 Lockdown on the Nasopharyngeal Microbiota of Children and Adults Self-Confined at Home. Rocafort M; Henares D; Brotons P; Launes C; Fernandez de Sevilla M; Fumado V; Barrabeig I; Arias S; Redin A; Ponomarenko J; Mele M; Millat-Martinez P; Claverol J; Balanza N; Mira A; Garcia-Garcia JJ; Bassat Q; Jordan I; Muñoz-Almagro C Viruses; 2022 Jul; 14(7):. PubMed ID: 35891502 [TBL] [Abstract][Full Text] [Related]
18. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study. Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796 [TBL] [Abstract][Full Text] [Related]
19. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial. Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826 [TBL] [Abstract][Full Text] [Related]
20. The Entero-Mammary Pathway and Perinatal Transmission of Gut Microbiota and SARS-CoV-2. Juárez-Castelán CJ; Vélez-Ixta JM; Corona-Cervantes K; Piña-Escobedo A; Cruz-Narváez Y; Hinojosa-Velasco A; Landero-Montes-de-Oca ME; Davila-Gonzalez E; González-Del-Olmo E; Bastida-Gonzalez F; Zárate-Segura PB; García-Mena J Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142219 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]